Tenaya Therapeutics announced that several abstracts have been accepted for presentation at the American Society of Gene and Cell Therapy, ASGCT, 26th Annual Meeting detailing the company’s expanded capabilities for manufacturing and discovering genetic medicines for heart disease. "Tenaya was founded with a singular focus on developing novel medicines for rare and prevalent forms of heart disease. To be a leader in this space requires a sustained commitment to differentiated platform capabilities that enable us to optimize the product profile for our therapeutic candidates and to address new conditions where there is high unmet need," said Faraz Ali, Chief Executive Officer of Tenaya. "The presentations at this year’s ASGCT highlight innovations in manufacturing, capsid engineering and gene editing, that support the advancement of our current pipeline and create new opportunities for future pipeline candidates. We look forward to sharing work on additional innovative enabling technologies and genetic medicine programs at future meetings."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TNYA:
- Tenaya Therapeutics Receives FDA Fast Track Designation for TN-201
- Tenaya Therapeutics receives FDA fast track designation for TN-201
- Oxford Biomedica appoints Leone Patterson as non-executive director
- Tenaya Therapeutics to Participate at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
- These 2 ‘Strong Buy’ Penny Stocks Could Rally to $40 (or More), Says Piper Sandler
